News

Patients with depression had a 37% higher risk of dying from their disease than patients without a mental health diagnosis.

Statistically and clinically meaningful improvements in invasive disease-free survival were observed among patients with hormone receptor–positive/HER2-negative early breast cancer who received ribociclib in addition to endocrine therapy.

Research published in the Clinical Journal of Oncology Nursing supports current guideline recommendations for washing clothes contaminated with cyclophosphamide.

The 3 year-pelvic recurrence rates with simple hysterectomy were comparable with those of radical hysterectomy among patients with low-risk, early-stage cervical cancer.

Each month, Oncology Nursing News® takes a look back at our most popular stories.

The FDA has approved olaparib for patients with BRCA-positive metastatic castration-resistant prostate cancer (mCRPC), as determined by an FDA-approved companion diagnostic test.

Patients with heavily pretreated advanced melanoma achieved responses with nivolumab and relatlimab.

Applying weighted blankets for 20 minutes reduced patient anxiety during cancer infusions.

The PET diagnostic imaging agent, flotufolastat F 18 injection has been approved by the FDA for the identification of prostate-specific membrane antigen–positive lesions in men with prostate cancer

Stephanie Jackson, DNP, MSN, RN, AOCNS, BMTCN, discusses how her institution improved double-check compliance with high-alert medications.

Updated National Comprehensive Cancer Network guidelines recommend ropeginterferon alfa-2b for patients with polycythemia vera.

Patients with metastatic breast cancer who received ribociclib plus fulvestrant achieved a median progression-free survival of 18.1 months vs 5.29 months with placebo/fulvestrant.

Manufacturers believe that GEN-002/avelumab holds promise as a third-line option for patients with gastric cancer and PD-L1 expression.

The FDA has granted priority review status to a breast cancer optical imaging agent, Lumisight.

Jessica MacIntyre, DNP, MBA, APRN, NP-C, AOCNP, describes how nurses used an app imbedded in the electronic medical record to refer patients to the Leukemia & Lymphoma Society.

Pediatric patients with leukemia in low- and middle-income countries saw improvements in survival outcomes following implementation of the WHO Framework for Action model.

A telephone-based weight loss program proved to be efficacious in overweight or obese women with breast cancer and may lead to improved disease outcomes in the long run.

Over half of patients with lower-risk myelodysplastic syndrome treated with luspatercept achieved transfusion independence.

Patients with pancreatic and gastric cancers residing in states with expanded Medicaid had improved survival rates.

Minimally invasive distal pancreatectomy was a safe and effective alternative compared with open distal pancreatectomy in patients with resectable pancreatic cancer.

Patient navigation services increased the rates of breast, cervical, and colorectal cancer screenings 6-fold amongst women living in rural communities.

The United Kingdom’s National Institute for Health and Care Excellence has updated their guidelines to recommend pembrolizumab plus lenvatinib for patients with previously treated endometrial cancer.

At the 48th Annual Oncology Nursing Society Congress, nurses shared how they improved travel nurse orientation at their institution.

Elizabeth Loach, MSN, APRN, CNS, AGCNS-BC, OCN, highlights how the Oncology Nurse Leader Council at her institution led to frontline nurse task-force engagement.

Fit patients with chronic lymphocytic leukemia achieved high undetectable minimal residual disease rates with frontline venetoclax combinations.

The FDA has approved avapritinib for the treatment of patients with indolent systemic mastocytosis.

Donna Catamero, ANP-BC, OCN, CCRC, highlights best nursing practices with teclistamab.

The FDA has issued a complete response letter for vic-trastuzumab duocarmazine.

Combined treatment with capivasertib plus fulvestrant yielded a 5.5-month median progression-free survival for patients with HR+ advanced breast cancer.

The FDA has granted epcoritamab accelerated approval for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. The prescribing label comes with boxed warnings for cytokine release syndrome and neurologic problems.